AllianceBernstein
CMPX icon

AllianceBernstein’s Compass Therapeutics CMPX Stock Holding History

AllianceBernstein’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$856K Buy
161,880
+77,940
+93% +$230K ﹤0.01% 2456
2026
Q1 		$451K Hold
83,940
– – ﹤0.01% 2695
2025
Q4 		$451K Sell
83,940
-20,220
-19% -$93.4K ﹤0.01% 2705
2025
Q3 		$365K Sell
104,160
-12,510
-11% -$39.5K ﹤0.01% 2852
2025
Q2 		$303K Buy
116,670
+95,230
+444% +$196K ﹤0.01% 2906
2025
Q1 		$40.7K Hold
21,440
– – ﹤0.01% 3153
2024
Q4 		$31.1K Sell
21,440
-2,740
-11% -$4.55K ﹤0.01% 3204
2024
Q3 		$44.5K Hold
24,180
– – ﹤0.01% 3196
2024
Q2 		$24.2K Buy
24,180
+10,700
+79% +$15.6K ﹤0.01% 3219
2024
Q1 		$26.7K Hold
13,480
– – ﹤0.01% 3116
2023
Q4 		$21K Hold
13,480
– – ﹤0.01% 3170
2023
Q3 		$26.6K Buy
13,480
+2,220
+20% +$5.49K ﹤0.01% 3164
2023
Q2 		$35.8K Buy
+11,260
New +$35.4K ﹤0.01% 3144

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

AllianceBernstein's CMPX Position: Q2 2026 in Review

AllianceBernstein increased its Compass Therapeutics (CMPX) stake by 93% in Q2 2026, buying an estimated $230K and bringing the position to 161,880 shares worth $856K. The position accounts for ﹤0.01% of the portfolio, ranked #2456.

AllianceBernstein first reported a position in CMPX in Q2 2023 and has held it in 13 quarters since. 216 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • AllianceBernstein held 161,880 shares of Compass Therapeutics worth $856K as of Q2 2026.
  • AllianceBernstein bought 77,940 Compass Therapeutics shares in Q2 2026, an estimated $230K.
  • Compass Therapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #2456 holding.
  • AllianceBernstein first reported a position in Compass Therapeutics in Q2 2023 and has held it in 13 quarters since.
  • 216 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.